Centessa Pharmaceuticals plc (CNTA) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-03-31

Key Insights

Centessa Pharmaceuticals has agreed to be acquired by Eli Lilly and Company for $38 per share in cash, plus up to $9 per share in contingent value rights (CVRs) tied to the achievement of certain milestones.
The transaction has been recommended by the boards of directors of both Centessa and Eli Lilly, and is subject to customary closing conditions including shareholder approval.
The agreement provides for the cancellation of Centessa's outstanding equity awards, with holders of options and restricted stock units to receive a combination of cash and CVRs.

Want the newest filings?

This analysis covers the filing from 2026-03-31. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-02-13

Centessa Pharmaceuticals announced the departure of its CEO, Saurabh Saha, M.D., Ph.D., who will transition to an advisory role, providing strategic guidance to the company.
The company has entered into an Advisory Agreement with Dr. Saha, compensating him on an hourly basis for his advisory services over an initial six-month period.
Under the Separation Agreement, Dr. Saha will receive accelerated vesting of his equity grants, a bonus payment, and continued eligibility for company benefits, in lieu of any other severance payments.

Other reports for Centessa Pharmaceuticals plc

Quarterly Report Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.